Gastroesophageal Junction Adenocarcinoma

• CLINICAL_TRIALS trial_result · 2025-08-29
  Clinical Trial Update: Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery [Phase 4]

  A Phase 4 trial update describing a study that compares postoperative adjuvant regimens of chemotherapy with or without immunotherapy in pat…

• CLINICAL_TRIALS trial_result · 2025-07-31
  Clinical Trial Update: Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

  A Phase 2 neoadjuvant trial evaluating trastuzumab, with or without pertuzumab, in patients with gastric or gastroesophageal junction adenoc…

• CLINICAL_TRIALS trial_result · 2025-07-08
  Clinical Trial Update: Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer [Phase 2]

  Phase 2 trial evaluating the combination of berzosertib with irinotecan for TP53-mutant advanced gastric or gastroesophageal junction cancer…

• CLINICAL_TRIALS trial_result · 2025-06-08
  Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers [Phase 1]

  Phase 1 trial updating on the addition of Adavosertib to radiation therapy in patients with incurable esophageal and gastroesophageal juncti…

• CLINICAL_TRIALS trial_result · 2025-06-06
  Clinical Trial Update: Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction Adenocarcinoma

  A completed neoadjuvant trial comparing nivolumab plus SOX versus nivolumab plus FLOT in HER2-negative gastric and gastroesophageal junction…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2025-06-04
  Clinical Trial Update: Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery [Phase 1, Phase 2]

  This update covers a Phase 1/2 trial of olaparib plus ramucirumab in patients with metastatic or locally recurrent gastric or gastroesophage…

• CLINICAL_TRIALS trial_result · 2025-05-29
  Clinical Trial Update: Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery [Phase 1]

  Phase 1 trial evaluating the addition of Telomelysin to chemoradiation for patients with advanced esophageal or gastroesophageal junction ad…

• CLINICAL_TRIALS trial_result · 2025-05-16
  Clinical Trial Update: A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer

  A completed clinical trial evaluating PET imaging with the radiotracer 18F-BMS-986229 in patients with cancers of the esophagus, stomach, or…

• CLINICAL_TRIALS trial_result · 2025-05-11
  Clinical Trial Update: A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON) [Phase 2]

  Phase 2 study evaluating IMU-131 (HER-Vaxx) with chemotherapy or pembrolizumab in metastatic HER2-overexpressing gastric cancer; the trial w…

• CLINICAL_TRIALS trial_result · 2025-03-27
  Clinical Trial Update: OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma [NA]

  Clinical trial OPPOSITE, studying outcome prediction of systemic treatment in esophagogastric carcinoma, has completed. The sponsor is Unive…

• CLINICAL_TRIALS trial_result · 2025-03-25
  Clinical Trial Update: Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer [Phase 1, Phase 2]

  Clinical trial update on Vactosertib combined with pembrolizumab for metastatic colorectal cancer and gastric/gastroesophageal junction aden…

• CLINICAL_TRIALS trial_result · 2025-03-17
  Clinical Trial Update: Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) [Phase 3]

  Phase 3 trial MK-3475-811/KEYNOTE-811 evaluating pembrolizumab plus placebo with trastuzumab and chemotherapy in HER2-positive advanced gast…

• CLINICAL_TRIALS trial_result · 2025-03-14
  Clinical Trial Update: SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas [Phase 1]

  Phase 1 trial evaluating SL-279252, a PD-1-Fc-OX40L fusion protein, in adults with advanced solid tumors or lymphomas has been completed wit…

• CLINICAL_TRIALS trial_result · 2025-03-12
  Clinical Trial Update: Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial [Phase 2]

  Phase 2 trial (NCT04510064) evaluated camrelizumab combined with nab-POF chemotherapy in patients with initially unresectable locally advanc…

• CLINICAL_TRIALS trial_result · 2025-03-10
  Clinical Trial Update: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors [Phase 2]

  Phase 2 trial of ladiratuzumab vedotin in multiple advanced solid tumors was terminated, with results posted in March 2025.

• CLINICAL_TRIALS trial_result · 2025-02-26
  Clinical Trial Update: A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer. [Phase 3]

  Phase 3 trial update comparing zolbetuximab plus chemotherapy versus placebo plus chemotherapy in adults with gastric and gastroesophageal j…

• CLINICAL_TRIALS trial_result · 2025-02-12
  Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 [Phase 1]

  This Phase 1 study of CMG901 in patients with advanced solid tumors, including gastric cancer and pancreatic cancer, assesses safety, tolera…

• CLINICAL_TRIALS trial_result · 2025-01-27
  Clinical Trial Update: A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). [Phase 3]

  A phase 3 trial (GLOW) evaluating zolbetuximab plus CAPOX versus placebo plus CAPOX in CLDN18.2-positive, HER2-negative gastric/GEJ adenocar…

• CLINICAL_TRIALS trial_result · 2025-01-27
  Clinical Trial Update: A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). [Phase 3]

  Phase 3 trial evaluating zolbetuximab plus CAPOX versus placebo plus CAPOX as first-line treatment for CLDN18.2-positive, HER2-negative loca…

• CLINICAL_TRIALS trial_result · 2025-01-22
  Clinical Trial Update: Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer [Phase 2, Phase 3]

  Clinical trial update reporting results from a Phase 2/3 study of tucatinib + trastuzumab + ramucirumab + paclitaxel vs paclitaxel + ramucir…

• CLINICAL_TRIALS trial_result · 2024-12-16
  Clinical Trial Update: BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors [Phase 1, Phase 2]

  BI-1607 in combination with Trastuzumab for HER2-positive advanced solid tumors (Phase 1/2) has been terminated. The study included HER2-pos…

• CLINICAL_TRIALS trial_result · 2024-11-25
  Clinical Trial Update: A Study of NDI 1150-101 in Patients With Solid Tumors [Phase 1, Phase 2]

  Nimbus Saturn, Inc. is conducting a Phase 1/2 trial of NDI 1150-101 in patients with solid tumors, including renal cell carcinoma, gastric c…

• CLINICAL_TRIALS trial_result · 2024-11-21
  Clinical Trial Update: Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens [Phase 2]

  Phase 2 study evaluating trastuzumab deruxtecan monotherapy in HER2-expressing gastric or GEJ adenocarcinoma after two or more prior regimen…

• CLINICAL_TRIALS trial_result · 2024-11-20
  Clinical Trial Update: A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma [Phase 1]

  This clinical trial update notes the completion of a Phase 1 pharmacokinetic study of zolbetuximab (IMAB362) in Chinese patients with locall…

• CLINICAL_TRIALS trial_result · 2024-11-14
  Clinical Trial Update: A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ) [Phase 2]

  A Phase 2 trial evaluating atezolizumab plus tiragolumab with chemotherapy in first-line HER2-negative unresectable, recurrent, or metastati…